泼尼松对转移性前列腺癌患者多西他赛药代动力学的影响:一项随机药物相互作用研究
本研究为前瞻性随机药代动力学交叉试验,纳入18例转移性前列腺癌患者,比较泼尼松(每日两次5 mg)联用与单用多西他赛(75 mg/m2)时的暴露量。结果显示多西他赛AUC0-inf在联用泼尼松时为2784 ng*h/mL(95%CI 2436-3183),单药时为2647 ng*h/mL(95%CI 2377-2949),无显著差异,且毒性谱相似。
要点
- 泼尼松每日两次5 mg不显著改变多西他赛AUC0-inf。
- 联用与单药的多西他赛毒性谱相似。
- 从药代动力学角度,多西他赛可与或不与泼尼松联用。
核心结论
- 泼尼松联用与单用多西他赛相比,多西他赛暴露量无显著差异。
- 两组毒性谱相似,从药代动力学角度多西他赛可与或不与泼尼松联用。
研究设计与样本
- 前瞻性随机药代动力学交叉试验,纳入计划接受至少6周期多西他赛(75 mg/m2)的转移性前列腺癌患者18例。
- 患者随机分配至前3周期或后3周期联用泼尼松(每日两次5 mg),于第3和第6周期进行药代动力学采血。
主要发现
- 联用泼尼松时多西他赛AUC0-inf为2784 ng*h/mL(95%CI 2436-3183),单药时为2647 ng*h/mL(95%CI 2377-2949)。
- 探索性分析显示单药与联用泼尼松周期之间毒性无差异。
临床怎么用
- 临床可依据药代动力学结果,在多西他赛方案中联用或不联用泼尼松(每日两次5 mg)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso-enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the liver, a potential drug-drug interaction may occur. In this prospective randomized pharmacokinetic cross-over study we investigated docetaxel exposure with concomitant prednisone, compared to docetaxel monotherapy in men with metastatic prostate cancer. METHODS: Patients scheduled to receive at least 6 cycles of docetaxel (75 mg/m2 ) and who gave written informed consent were randomized to receive either the 1st 3 cycles, or the last 3 consecutive cycles with prednisone (twice daily 5 mg). Pharmacokinetic blood sampling was performed during cycle 3 and cycle 6. Primary endpoint was difference in docetaxel exposure, calculated as area under the curve (AUC0-inf ) and analysed by means of a linear mixed model. Given the cross-over design the study was powered on 18 patients to answer the primary, pharmacokinetic, endpoint. RESULTS: Eighteen evaluable patients were included in the trial. Docetaxel concentration with concomitant prednisone (AUC0-inf 2784 ng*h/mL, 95% confidence interval 2436-3183 ng*h/mL) was similar to the concentration of docetaxel monotherapy (AUC0-inf 2647 ng*h/mL, 95% confidence interval 2377-2949 ng*h/mL). Exploratory analysis showed no toxicity differences between docetaxel monotherapy and docetaxel cycles with prednisone. CONCLUSION: No significant difference in docetaxel concentrations was observed. In addition, we found similar toxicity profiles in absence and presence of prednisone. Therefore, from a pharmacokinetic point of view, docetaxel may be administrated with or without prednisone.
引用
- Belderbos BPS, Hussaarts KGAM, van Harten LJ, et al. Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study. Br J Clin Pharmacol. 2019. PMID: 30737835. doi:10.1111/bcp.13889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。